{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-026282","form_type":"8-K","ticker":"PBYI","cik":"0001401667","company_name":"PUMA BIOTECHNOLOGY, INC.","filed_at":"2026-08-06T20:19:37+00:00","discovered_at":"2026-08-06T20:21:00.308972+00:00","generated_at":"2026-08-06T20:22:41.551199+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Puma Biotech Q2 net income $8.2M, raises 2026 guidance on NERLYNX demand","bullets":["Q2 product revenue $53.6M (+9% YoY); GAAP net income $8.2M ($0.16/sh) vs $5.9M ($0.12/sh) in Q2 2025.","Non-GAAP adjusted net income $10.1M ($0.20/sh basic) vs $7.5M ($0.15/sh) prior year.","Raises FY 2026 net product revenue guidance to $205-209M (prior $202-206M); net income to $17-20M (prior $16-19M).","Debt fully repaid in May 2026; cash & securities $93.9M at June 30, 2026.","R&D expenses rose $9.4M YTD on alisertib trial activity; milestones include ALISCA-Lung2 initiation in Q3 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-026282","json":"https://secwatch.observer/filing/0001437749-26-026282.json","markdown":"https://secwatch.observer/filing/0001437749-26-026282.md","text":"https://secwatch.observer/filing/0001437749-26-026282.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401667/000143774926026282/0001437749-26-026282-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401667/000143774926026282/pbyi20260608_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:22:41.551199+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}